ADC Therapeutics SA ADCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
-
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
-
ADC Therapeutics to Present at Upcoming Investor Conferences
-
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
-
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
-
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
-
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
Trading Information
- Previous Close Price
- $3.05
- Day Range
- $3.09–3.36
- 52-Week Range
- $0.36–6.04
- Bid/Ask
- $3.21 / $3.30
- Market Cap
- $318.10 Mil
- Volume/Avg
- 263,249 / 405,076
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.22
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 274
- Website
- https://www.adctherapeutics.com
Comparables
Valuation
|
Metric
|
ADCT
|
MLTX
|
EPIX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 6.68 | 2.08 |
Price/Sales | 4.22 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADCT
|
MLTX
|
EPIX
|
|---|---|---|---|
Quick Ratio | 5.60 | 42.46 | 36.61 |
Current Ratio | 6.17 | 43.71 | 36.95 |
Interest Coverage | −2.85 | — | −29,635.69 |
Quick Ratio
ADCT
MLTX
EPIX
Profitability
|
Metric
|
ADCT
|
MLTX
|
EPIX
|
|---|---|---|---|
Return on Assets (Normalized) | −51.81% | −9.89% | −15.52% |
Return on Equity (Normalized) | — | −10.56% | −15.94% |
Return on Invested Capital (Normalized) | −1,069.85% | −10.07% | −19.88% |
Return on Assets
ADCT
MLTX
EPIX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Dgmpzqwlc | Gcxbl | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wrspjfxt | Jsglfjb | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yrqbkcm | Yrzjxc | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zzfdyfrl | Llfpl | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Gjnrjnty | Srgrz | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Pxwwbps | Wmj | $29.2 Bil | |||
| Moderna Inc
MRNA
| Ctzxxyzg | Ndf | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Grxkpgq | Pdgkd | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ybxymftm | Slskvr | $13.2 Bil | |||
| Incyte Corp
INCY
| Bbnrggkx | Fllqhgf | $13.0 Bil |
United States